09:45 AM EDT, 07/11/2024 (MT Newswires) -- Biodexa Pharmaceuticals ( BDRX ) said Thursday that 12-month data from a mid-stage clinical trial showed the longevity of effect of eRapa in the treatment of precancerous polyps in the gastrointestinal tract.

The company said that based on the data, eRapa showed an overall 17% median decrease in overall polyp burden and non-progression rate of 75%.

Biodexa said that in one group, 89% of patients were considered non-progressors at 12 months, with a 29% median reduction in polyp burden.

The company said that a person with the condition will have a 100% chance of developing colorectal cancer if left untreated.

Shares of Biodexa jumped 101% in recent Thursday trading.

Price: 1.29, Change: +0.58, Percent Change: +81.41